Amylyx Pharmaceuticals, Inc. (AMLX)
34.49
+0.68
(+2.01%)
USD |
NASDAQ |
Sep 02, 16:00
34.80
+0.31
(+0.90%)
After-Hours: 06:51
Amylyx Pharmaceuticals Research and Development Expense (Annual) : 89.88M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 89.88M |
| December 31, 2024 | 103.18M |
| December 31, 2023 | 127.10M |
| December 31, 2022 | 93.45M |
| Date | Value |
|---|---|
| December 31, 2021 | 44.04M |
| December 31, 2020 | 24.59M |
| December 31, 2019 | 11.90M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc. | 10.25B |
| Eli Lilly & Co. | 13.34B |
| Merck & Co., Inc. | 12.51B |
| EyePoint, Inc. | 221.04M |
| Bristol Myers Squibb Co. | 9.492B |